Company / EPS (Basic)
VYNE Therapeutics Inc. EPS (Basic) History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Basic)
-$0.93
FY2025
5-year range
-$25.64 / $7.88
FY2021-FY2025
Trend
+66.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Basic) has increased for 3 consecutive years, from $-25.64 in FY2022 to $-0.93 in FY2025.
Based on SEC 10-K filings.
-0.93 in FY2025.
Improved from $-7.28 to $-0.93 over the past 2 years.
EPS (Basic) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- VYNE Therapeutics Inc.'s eps (basic) has grown for 3 consecutive years.
- In FY2025, eps (basic) increased 66.5% year-over-year.
- Peak eps (basic) was recorded in FY2021.
- Lowest eps (basic) in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Basic)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.93 | +66.5% |
| FY2024 | -$2.78 | +61.8% |
| FY2023 | -$7.28 | +71.6% |
| FY2022 | -$25.64 | -425.4% |
| FY2021 | $7.88 | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026